BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

NCT02209753 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

182

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: BIRB 796 BS, low dose
DRUG: BIRB 796 BS, medium dose 1
DRUG: BIRB 796 BS, medium dose 2
DRUG: BIRB 796 BS, high dose
DRUG: Placebo

Sponsor

Boehringer Ingelheim